All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Vincent Camus, Centre Henri-Becquerel, Rouen, FR. We asked, What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma (PMBL)?
What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma?
PMBL is a rare form of B-cell lymphoma mostly affecting younger female patients, and the optimal treatment for it is uncertain. Camus presents a large retrospective analysis, across Lymphoma Study Association (LYSA) centers, on patients with newly diagnosed PMBL. This analysis compared CHOP delivered every 21 days (CHOP21), CHOP delivered every 14 days (CHOP14), and ACVBP, all combined with rituximab.
R-CHOP versus DA-EPOCH-R as frontline therapy for DLBCL: Results from a phase III trial
In this randomized, Alliance/CALGB 50303 study (NCT00118209), the efficacy and safety of DA-EPOCH-R and R-CHOP were compared as frontline treatment for patients...
Preparing for ASH 2020| Advances in ctDNA for lymphoma prognosis
The Lymphoma Hub is looking forward to attending the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which will take place in a virtual format on December 5–8,...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox